Certolizumab pegol has been approved in Canada for treating adults with plaque psoriasis. The U.K. has also issued its final guidance for the treatment’s use…
Search results for: psoriasis
FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA
Certolizumab pegol is now FDA approved to treat adults with active non-radiographic axial spondyloarthritis…
Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…
State Step Therapy Laws: Not All Are Created Equal
Step therapy reform has been a hot topic and major focus of the ACR’s advocacy activity in states this legislative session. Washington, Oregon, Wisconsin and Florida are all considering step therapy bills that stand good chance of passing this legislative year. Virginia and Georgia have already passed step therapy laws. When these two new laws…
FDA Approves Guselkumab Injector
The FDA has approved a single-press, self-injection device for a 100-mg dose of guselkumab for adults with moderate to severe plaque psoriasis…
The Latest on Vaccinations, Leprosy & Lyme Disease
CHICAGO—Keith Winthrop, MD, MPH, professor of public health and preventive medicine at the Oregon Health & Science University School of Medicine, Portland, Ore., began the vaccination session at the 2018 ACR/ARHP Annual Meeting with a review of vaccination timing and targets. He presented a clinically relevant snapshot of the vaccines rheumatologists should consider and emphasized…
The Latest on Epigenetics in Immune-Mediated Disease
CHICAGO—Because the epigenome has been implicated in a variety of rheumatic conditions, a Basic Research Conference was convened on Epigenetics in Immune-Mediated Disease in conjunction with the 2018 ACR/ARHP Annual Meeting. Melanie Ehrlich, PhD, professor of human genetics and genomics at Tulane University School of Medicine, New Orleans, opened the conference. She has a long…
State-of-the-Art Approaches to Rheumatic Disease Diagnosis, Management & Treatment
CHICAGO—Held during the 2018 ACR/ARHP Annual Meeting, the ACR Review Course covered a wide range of topics for rheumatologists—from advances in pain and rheumatic disease management to the intersection of rheumatology and neurology. Session speakers shared insights, as well as state-of-the-art approaches to diagnosis, management and treatment. Inflammatory Myopathies Julie J. Paik, MD, MHS, assistant…
Recent Research Probes Smoking & the Risk for Autoimmune Disease
It’s no secret to any health professional, including rheumatologists, that smoking cigarettes or using other tobacco-based products is unhealthy. Yet how does smoking specifically affect rheumatic diseases, and what are some of the newest findings in this area? What role do e-cigarettes have in the smoking risk landscape? Those are the sorts of questions asked…
When Immunodeficiency & Autoimmunity Coexist
CHICAGO—Although rare, when a patient has both primary immune deficiency and autoimmune disease, the combination can lead to life-threatening complications requiring careful, long-term therapy. In When Immune Deficiency and Autoimmunity Coexist, a session at the 2018 ACR/ARHP Annual Meeting, M. Eric Gershwin, MD, the Jack and Donald Chia professor of Medicine and chief of Rheumatology,…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 55
- Next Page »